Initial attempts of targeting CEA by humanized anti‐CEA antibodies have led to disappointing results, probably because a shedding of CEA from tumour cells caused a binding of therapeutic antibodies to circulating CEA in the blood stream, which prevented these antibodies from reaching the tumour cells (summarized in Gold et al.33). The gene discussed is CEACAM5; the disease is neoplasm.